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Objective: Thoracic lymph node recurrence after complete resection is 
common in non–small-cell lung cancer but it mostly occurs along with 
distant metastases. The recurrent disease might be localized and cura-
tive intent radiation therapy is the treatment of choice if no evidence of 
hematogenous metastasis is observed. We sought to describe the out-
comes of thoracic radiotherapy for thoracic lymph node recurrences.
Methods: Fifty patients who had developed thoracic lymph node 
recurrence after complete resection received curative intent radio-
therapy between 1997 and 2009. The clinical endpoints included the 
tumor response, overall survival, progression-free survival, locore-
gional recurrence within the irradiated field, and any other recurrence.
Results: The planned total radiotherapy was completed in 49 patients 
with minor toxicity. The median follow-up time after radiotherapy was 
41 (19–98) months among the survivors. The response to treatment 
was complete response in 65%, partial response in 24%, and progres-
sive disease in 10% of the evaluated patients. The median overall sur-
vival after radiotherapy was 37.3 months. The 5-year overall survival, 
progression-free survival, and local control rate were 36.1%, 22.2%, 
and 61.1%, respectively. A multivariate analysis revealed that the 
absence of symptoms and the involvement of a single lymph node sta-
tion were significant factors associated with a better overall survival.
Conclusions: Radiation therapy for thoracic lymph node recurrence 
after complete resection is safe and provides acceptable disease con-
trol. This treatment provides a better outcome if the disease is asymp-
tomatic and has a single-station involvement. Early detection of the 
recurrence may thus improve the effectiveness of this treatment.
Key Words: Radiotherapy, Lymph node recurrence, Non–small-cell 
lung cancer.
(J Thorac Oncol. 2013;8: 1417–1424)
Recurrence after surgery is common in patients with non–small-cell lung cancer (NSCLC). Once the disease has 
relapsed after surgery, it is seldom curable and the median 
survival time after recurrence is estimated to be 8.1 to 18.7 
months.1–3 Most recurrences occur in multiple sites including 
distant organs, thus chemotherapy is commonly used for this 
systemic state of the disease.4
Thoracic lymph node recurrence is one of the excep-
tions when there is no evidence of hematogenous spreading 
of the disease. The recurrent disease might be still localized in 
these patients and curative intent radiation therapy is the treat-
ment of choice.5 However, the efficacy and feasibility of radio-
therapy for thoracic lymph node recurrence after a complete 
resection have not yet been clearly described. We retrospec-
tively reviewed our experience to determine (1) progression-
free survival, patterns of failure, and local control, (2) overall 
survival and associated factors, and (3) treatment compliance 
and toxicity.
PATIENTS AND METHODS
Patients
This study conducted a retrospective review of 1553 
patients who underwent complete resection for NSCLC at 
the Osaka Medical Center for Cancer and Cardiovascular 
Diseases, Japan, from January 1997 to December 2009. The 
ethics committee gave its approval for the publication of this 
retrospective study. The institutional prospective database of 
the general thoracic department included clinicopathological 
variables at surgery and the postoperative clinical course. The 
inclusion criteria for this study were patients with lymph node 
recurrence as the initial recurrence, which included intratho-
racic lymph nodes and supraclavicular lymph nodes and that 
received radiation therapy for the recurrence. Patients with 
any other recurrence except the thoracic lymph nodes were 
excluded. The method how the patients were selected from the 
database was shown in a CONSORT chart (Fig. 1). Finally, we 
identified 50 patients who received radiotherapy for thoracic 
lymph node recurrence. The characteristics of these patients 
are summarized in Table 1. There were 17 patients with tho-
racic lymph node recurrence who did not receive radiotherapy.
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The follow-up protocol for postoperative patients at 
this institution included a physical examination, chest radio-
graph, and blood testing including the value of carcinoembry-
onic antigen (CEA) every 3 to 6 months, and chest computed 
tomography (CT) every 6 to 12 months for at least 5 years. 
If patients were suspected of having developed recurrent dis-
ease, they were instructed to undergo systemic examinations 
including upper abdominal CT or abdominal echography, 
brain magnetic resonance imaging, and bone scintigraphy 
or 18F-fluorodeoxy glucose-positron emission tomography 
(FDG-PET) before determining the treatment strategy. After 
undergoing thoracic radiotherapy, the patients were recom-
mended to have more follow-up visits (every 1–3 months dur-
ing the first 3 years) by surgeons and/or radiation oncologists. 
Six patients received concurrent systemic intravenous chemo-
therapy with radiotherapy.
Diagnosis of Lymph Node Recurrence
The diagnosis and status of lymph node recurrence 
of the patients who received radiotherapy are summarized 
in Table 1 (n = 50). The diagnosis of lymph node recur-
rence was based on the radiological findings of chest CT, 
FDG-PET, physiological examination, the value of CEA, 
and/or bronchoscopic sampling for cytology. Among 50 
eligible patients, the cytological evidence was obtained in 
10 patients (20%). Swollen lymph nodes exhibited signifi-
cantly increased standard uptake values on PET scans in 
31 patients (62%), and growing lymph nodes detected on 
at least two consecutive CT scans were observed in nine 
patients (18%). In these patients, radiotherapy was com-
menced without conducting further interventional exami-
nations to obtain cytological evidence because lymph node 
recurrence was apparent on the radiological findings. The 
status and the treatment of recurrent diseases of the patients 
who did not receive radiotherapy are summarized in Table 2 
(n = 17). There were more symptomatic diseases, more N3 
level recurrences, and more multistation involvements in 
this group.
Protocol of Radiotherapy
The patients were treated using three-dimensional con-
formal techniques using a CT-based planning system (Eclipse; 
Varian Medical Systems, Palo Alto, CA). The gross tumor vol-
ume (GTV) was defined based on the assessment of the involved 
nodal region in the CT images. In addition, lymph nodes that 
were positive for FDG accumulation by PET/CT were included 
in the GTV, even if their sizes were within the normal limits on 
CT. The clinical target volume was defined as the GTV plus 
a 5-mm margin. Two different radiotherapeutic approaches, 
regional nodal irradiation and involved-field irradiation, were 
used in this study. Regional nodal irradiation covered two or 
more areas of five thoracic lymph node areas (right- and left- 
hilar areas, superior mediastinum area, supraclavicular area, 
and subcarinal area) in the GTV whether or not involved lymph 
nodes were present in the stations, whereas the involved-field 
irradiation covered only metastatic lymph nodes regardless of 
the anatomical compartment of thoracic lymph node areas. 
Radiotherapy was not systematically performed according to 
the predetermined protocol for all cases. Basically, a regional 
nodal irradiation approach was considered the first choice for 
all patients, but if the coverage of all involved stations elevated 
normal tissue toxicity or the patients had impaired medical con-
ditions, the involved-field irradiation technique was applied. 
The treatment approach was determined on an individual basis 
by the experienced radiation oncologist (Table 1). Planning 
treatment volume denoted the clinical target volume and 5 to 
15 mm margins for geometric uncertainties and respiratory 
motion. The prescribed dose was calculated with a heteroge-
neous dose calculation algorithm (pencil beam convolution or 
anisotropic analytical algorithm). Conventional fractionation 
was used (2–3 Gy per fraction) and the preplanned radiation 
dose ranged from 60 to 66 Gy in 43 patients. In four patients, 
the dose was reduced to 50 Gy because of the radiation field 
and/or patient’s medical condition. In three patients, the dose 
was increased up to 70 to 84 Gy. Treatment was delivered 
using 6- or 10-MV photons of the linear accelerator (Clinac 
2100C/23EX; Varian Medical systems). Dose prescription was 
defined according to International Commission on Radiation 
Units and Measurements recommendations.
Clinical Endpoints
Clinical endpoints after radiotherapy included the over-
all survival, progression-free survival, tumor response, and 
locoregional recurrence within the irradiated field and any 
other recurrence. All responses were evaluated 3 to 6 months 
after the completion of radiotherapy based on follow-up CT 
and/or PET scan. Complete response (CR) was defined as the 
shrinking of metastatic nodes to normal size (the longest diam-
eter was <10 mm) on chest CT without significant accumula-
tion of FDG on PET. The value of CEA was also required to be 
within the normal limit if it was elevated before the radiother-
apy. Partial response required more than 30% reduction of the 
longest diameter. Progressive disease was defined as increase 
of more than 20% of the longest diameter and/or progression 
of any other recurrent disease. Local tumor recurrence was 
defined as progressive abnormal CT images within the irradi-
ated field during the follow-up period. The time of recurrence 
FIGURE 1.  A flow chart of the patient selection. NSCLC, 
non–small-cell lung cancer.
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was recorded using the interval-censored techniques. The 
duration of survival and time to failure were determined from 
the initiation of the radiation therapy until the date of death 
and the time of recurrence, respectively. The patients lost to 
the follow-up were censored at the date of last contact with the 
institution. Toxicity was assessed using the National Cancer 
Institute Common Toxicity Criteria scale version 2.0.
Statistics
Survival was calculated by the Kaplan–Meier method, 
and differences in survival were assessed by a log-rank analy-
sis. The factors whose p values were less than 0.10 (border-
line significant) in the univariate analysis in Table 1 were 
further examined using a multivariate analysis. A multivariate 
analysis for prognostic factors was performed using the Cox 
TABLE 1.  Patient Characteristics, the Diagnosis, and Status of Lymph Node Recurrence, and Treatment Protocol of Thoracic 
Radiotherapy
Variables N = 50 Univariate Analysis for Overall Survival, p
Age at LN recurrence, years old 0.6915 (≤67 vs. >68)
  Median (range) 68 (48–84)
Sex (male/female) 42/8 0.4085
Smoking status (nonsmoker/smoker) 11/39 0.9443
Primary site
  Right/left 32/18 0.5459
  Upper or middle/lower 31/19 0.7960
Surgery
  Limited resection (wedge/segmentectomy) 6 (3/3) 0.5875
  Standard surgery (lobectomy/bilobectomy/pneumonectomy) 44 (39/4/1)
Histology (adenoca/squamous/others) 21/27/2 0.5706
Stagea at surgery 0.5723 (I or II vs. III)
  IA/IB/IIA/IIB/IIIA 11/3/10/0/26
Disease-free interval after surgery, days 0.2965 (≤365 vs. >365)
  Median 324
  Range 86–3088
Diagnostic procedure
  Patho- or cytological examination 10
  PET/CT 31
  CT (+symptom or elevated CEA) 9
Number of stations (single/multiple) 30/20 0.0457
Site of LN recurrence 0.2331 (N1 vs. N2/N3)
  N1 level
   Ip–hilar only 10
  N2 level
   Upper med. (+ip–hilar) 19
   Lower med. (+ip–hilar) 5
   Upper and lower med. (+ip–hilar) 4
  N3 level
   SC (+upper or lower med.) 10
   Cl–hilar and upper med. 2
Symptoms at recurrence (bpresent/absent) 13/37 0.0017
Maximum diameter of involved LN (mm) 0.4784
  20 or smaller/21 or larger 26/24
Radiation approach 0.3853
  Regional nodal/involved-field 23/27
Radiation dose (Gy) 0.4325 (≤60 Gy vs. >60 Gy
  50~59/60~69/70~ 4/43/3
Concurrent chemotherapy 0.6185
  Yes/no 6/54
aThe stages were described according to the 7th edition.
bDetails are cough in seven patients, sputum production in five patients, bloody sputum in two patients, breathlessness in two patients, and hoarseness in two patients.
LN, lymph node; PET, positron emission tomography; CT, computed tomography; Ip–hilar, ipsilateral hilar; med., mediastinal; SC, subclavicular; cl–hilar, contralateral hilar.
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proportional hazard regression model. p values less than 0.05 
were considered to be statistically significant. The statistical 
analyses were carried out using the JMP 8 software package 
(SAS Institute, Cary, NC).
RESULTS
Response to Treatment
Response to treatment was evaluated in all patients 
but one who died of another cause 4 months after the radia-
tion treatment. Thirty-two of 49 patients (65%) had CR, 
12 (24%) had partial response, and five (10%) had progres-
sive disease. A univariate analysis showed that there were 
no variables associated with the response when patients’ 
response to treatment was divided into with CR and the 
others. An example of a CR is shown in Figure 2. Relief 
of the associated symptoms was achieved after radiotherapy 
in 12 of 13 symptomatic patients. There were 16 patients 
with elevated CEA values before radiotherapy. Among them, 
the CEA values responded to radiotherapy in 13 patients 
(81%), and nine patients (56%) exhibited normal CEA val-
ues after radiotherapy.
Progression-Free Survival, Patterns of Failure, 
and Local Control after Radiotherapy
The median follow-up period after radiation therapy 
among the survivors was 41 months (range, 19–98 months). 
Two patients were lost to follow-up at 50 and 73 months after 
radiotherapy. The remaining survivors received the follow-
up per the protocol and the recommendation until this study 
was closed. Disease progression after radiation therapy was 
observed in 36 patients (72%). Progression-free survival after 
radiotherapy is shown in Figure 3A. The 1-, 3-, and 5-year 
progression-free survival rates were 49.1%, 28.2%, and 
22.2%, respectively. The median progression-free interval was 
12.0 months after radiotherapy. Ten (23%) of 43 patients who 
were followed up for more than 3 years showed no additional 
recurrence after radiotherapy. The initial sites of the disease 
progression are summarized in Table 3. In-field recurrence 
was observed in 18 patients (36%) during their entire follow-
up period. The probability of local control is shown by the 
Kaplan–Meier method in Figure 3B. The 3- and the 5-year 
local control rates were 65.9% and 61.1%, respectively. The 
incidence of initial recurrence in thoracic lymph nodes and 
the in-field recurrence rate were not associated with the radio-
therapeutic approach.
Overall Survival and Prognostic Factors  
after Radiotherapy
Twenty-seven patients (54%) died of lung cancer and 
two patients (4%) died of other causes within a 5-year follow-
up period. The overall survival probability is shown in Figure 
3C. The 1-, 3-, and 5-year overall survival rates were 84.0%, 
52.7%, and 36.1%, respectively. The median overall survival 
was 37.3 months after radiotherapy. A univariate analysis was 
used to evaluate the prognostic impact of 16 clinicopathologi-
cal factors listed in Table 1. The absence of symptoms and a 
single involved lymph node station at recurrence were signifi-
cant favorable prognostic factors but others were not. A mul-
tivariate analysis showed that the absence of symptoms and 
single involved lymph node station were significant indepen-
dent factors associated with the overall survival (Table 4). The 
median overall survival was 45.4 months for nonsymptomatic 
patients and 48.9 months for patients with a single involved 
lymph node station. There were 23 patients (46%) patients 
who were both nonsymptomatic and with single involved 
TABLE 2.  The Status and the Treatment of Recurrent 
Diseases in the Patients Who Did Not Receive Radiotherapy
Variables N = 17
Disease-free interval after surgery, days 482 (97–1297)
Number of stations Single/multiple 1/16
Site of LN recurrence N1 level 0
N2 level 6
N3 level 11
Symptoms at recurrence Present/absent 9/8
Maximum diameter of 
involved LN
20 or smaller/21 or larger 7/10
Treatment for recurrence Chemotherapy 10
EGFR-TKI therapy 2
Supportive care 5
Reason why radiotherapy was 
not chosen
Extensive lymph node 
recurrence
6
Lung fibrosis/COPD 7
Others 4
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; COPD, 
chronic obstructive pulmonary disease; LN, lymph node.
FIGURE 2.  An example of complete response to radio-
therapy for postoperative lymph node recurrence. PET 
scans of the whole body were obtained at baseline (A) and 
after 6 months of radiotherapy (B). PET, positron emission 
tomography.
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lymph nodes station. The overall survival probability of those 
patients and the remaining patients are shown in Figure 3D. 
The initial sites of the disease progression were not associ-
ated with these factors. The use of concurrent chemotherapy 
did not affect the overall or progression-free survival. There 
were five patients who had single-station lymph node recur-
rence in the supraclavicular area. Two of these patients sur-
vived more than 3 years after radiotherapy without any other 
disease recurrences.
Treatment Compliance and Toxicity
The planned total radiotherapy dose was delivered to 
49 patients (98%) of 50 patients. One patient (2%) developed 
grade 2 pneumonitis and esophagitis at 56 Gy/60 Gy and 
refused further therapy. The remaining patients showed acute 
toxicity of grade 2 in six patients (12%) (esophagitis, pneu-
monitis, malaise, and arthralgia), acute toxicity of grade 3 in 
one patient (2%; dyspnea), and late toxicity of grade 3 in one 
patients (2%; pneumonitis). Grade 3 toxicities were observed 
in patients receiving regional nodal radiotherapy.
Overall Survival of the Patients Who 
Did Not Receive Radiotherapy
The overall probability of survival of the patients who 
did not receive radiotherapy is shown in Figure 4. The median 
survival was 443 days, and the 1-year and the 3-year survival 
probabilities were 58.8% and 5.9%, respectively.
DISCUSSION
Many of the patients who undergo radical resection for 
NSCLC develop recurrence with a dismal prognosis. The use 
of chemotherapy is generally recognized as a standard option 
to provide objective responses and small improvement in sur-
vival for patients with recurrent disease just as performed for 
initial stage IV patients.
Postoperative lymph node recurrence is common but it 
mostly occurs along with distant metastases.4 Systemic ther-
apy would be indicated for patients with recurrences in both 
lymph nodes and a distant organ. However, the disease is con-
sidered to be localized if thoracic lymph nodes are involved 
but no other metastasis is observed after systematic workup, 
FIGURE 3.  Plots of the progression-free survival (A), local control (B), and overall survival (C) probabilities with 95% con-
fidence intervals (dash lines) among patients who received radiotherapy for thoracic lymph node recurrence after surgery. 
Plots of the overall survival (D) probabilities in the patients who were both nonsymptomatic and with single involved lymph 
nodes station (n = 23, bold line) and the patients who were symptomatic or with multiple involved lymph nodes stations 
(n = 27, faint line).
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and these patients may have a chance to be cured. A report of 
the anatomic location of NSCLC recurrences in 378 patients 
showed that there were 30 mediastinal lymph node recurrences 
(7.9%).6 Curative intent radiotherapy can be indicated for this 
specific state of the disease. The database of this institution 
yielded 50 patients who underwent thoracic radiotherapy in 
this setting, and the short- and the long-term outcomes of this 
treatment were analyzed. The treatment was completed in most 
of the patients and no serious complications were recorded. The 
median overall survival was 37 months and the 5-year survival 
rate was 36.1%. Ten (20%) of 50 patients were alive longer 
than 3 years without any additional recurrence after the radio-
therapy. These results suggest that a subset of patients with 
postoperative lymph node recurrence may be cured or enjoy a 
long-lasting progression-free survival by thoracic radiotherapy.
To date there have been few reports that summarize the 
treatments for recurrent disease in the literature.1–3,7 Previous 
reports show that the median postrecurrent survival ranges 
from 8.1 to 18.7 months. Limiting the results to the patients 
who underwent radiotherapy for lymph node recurrence or 
other locoregional recurrence shows a median survival after 
recurrence of 14 to 15 months.5,8–10
The CEA values were used for monitoring the treatment 
effects in this study. The normal CEA values were required 
for the CR definition after radiotherapy, although the use of 
CEA in NSCLC remains controversial. Several reports have 
indicated that elevated serum CEA levels are associated with 
an unfavorable prognosis and occult lymph node metastasis 
in NSCLC patients.11,12 Indeed, we observed several patients 
whose lymph nodes shrank to normal size by radiotherapy but 
their CEA levels were still elevated comparing with the nor-
mal limit. By using the size criteria only, we might overesti-
mate the CR rate.
The outcomes in the current study were favorable as a 
treatment for recurrent disease. The CR rate was as high as 
65%. The median survival and the 5-year survival rate in the 
present series were considerably longer than those of previous 
reports.5,8–10 This is partially because of significant improve-
ments in conformal radiotherapy within the past one or two 
decades, which have enabled the use of intensive radiotherapy 
to treat recurrent disease with less radiation toxicity. Another 
reason may exist in the differences in patient backgrounds. 
More patients with associated symptoms were included and 
the size of the recurrent tumor was larger in the previous stud-
ies. In contrast, the disease was nonsymptomatic, the involved 
lymph nodes were localized in only one station, and the size 
of the target tumor was smaller than 30 mm in many of the 
patients in this study.
The prognostic impact of variables was evaluated by 
univariate and multivariate analyses to select the patients who 
may benefit most from this treatment. The analysis revealed 
TABLE 3.  Initial Site of Disease Progression after 
Radiotherapy
Site Number of Patients
Pulmonary metastasis or pleural dissemination 11
Extrathoracic distant metastasis 7
Lymph nodes out of the radiation field 9
Lymph nodes within the radiation field 9
Alive without the disease 14
TABLE 4.  Multivariate Analysis of Overall Survival after 
Radiotherapy
Variable Reference HR 95% CI p
Symptom Absent 3.86 1.72–8.57 0.0014
Number of stations Single 2.70 1.21–6.12 0.0152
Cox proportional hazard model.
HR, hazard ratio; CI, confidence interval.
FIGURE 4.  Plots of the overall 
survival probabilities with 95% con-
fidence intervals (dash lines) among 
patients who did not receive radio-
therapy (n = 17).
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that absence of symptoms at the time of recurrence and a 
single involved lymph node station were favorable prognos-
tic indicators after recurrence. Interestingly, both prognostic 
factors in this study were associated with early presentation 
of recurrence. The surveillance program in this institution, 
which includes chest CT one or two times a year is relatively 
intensive in comparison with the guideline-recommended 
programs.13 PET scan was also useful, because PET distin-
guished thoracic lymph node recurrence from nonspecific 
postoperative change. The intensive surveillance using chest 
CT and PET may play an important role in the early diag-
nosis of lymph node recurrence. The results of the present 
study and the comparisons with previous studies suggest that 
early detection of recurrence after surgery may contribute to 
achieving good disease control after radiation and, as a result, 
longer survival.
A favorable local control rate within the irradiated field 
was obtained by thoracic radiotherapy without any severe 
adverse events. The radiation dose prescribed in this study 
was considered to be adequate. Radiotherapeutic approaches 
in this study were classified into regional nodal irradiation 
and involved-field irradiation. Regional nodal radiation ther-
apy covers a larger field and, as a result, may allow more 
irradiation to adjacent organs such as lung and esophagus, in 
comparison with involved-field radiation, which targets only 
metastatic nodes. Local recurrence-free survival or patterns 
of failure after radiotherapy were not associated with the 
choice of the radiation approach. On the basis of this result, 
restricting the target volume to the involved nodal regions 
might be an option as a radiation approach for thoracic 
lymph node recurrence. These phenomena were similarly 
observed in the comparison between elective nodal irradia-
tion and involved-field irradiation for locally advanced unre-
sectable NSCLC.14,15
Systemic chemotherapy is a mainstay of treatment for 
recurrent NSCLC. Only a small number of patients received 
concurrent chemotherapy in this study. Considering that 
concurrent chemoradiotherapy is a standard treatment for 
the patients with inoperable stage III NSCLC, this approach 
can be another option for regional lymph node recurrence 
after surgery. When selecting the treatment strategy for 
patients with thoracic lymph node metastases, it should be 
noted that there were essential differences between stage III 
NSCLC and postoperative recurrences. First, the primary 
tumor had been resected in postoperative patients. Second, 
the nodal disease was observed after at least a few months of 
disease-free status. In addition, the sizes of involved lymph 
nodes were relatively small and their distribution was lim-
ited to a couple of stations in most of the recurrent patients. 
Therefore, thoracic lymph node recurrences were consid-
ered to be local disease, and curative intent radiation therapy 
was the treatment of choice. In contrast, the involved lymph 
nodes in inoperable stage III patients are usually bulky 
and extended to multiple nodal stations. Consequently, the 
prognostic advantage was not observed in the patients who 
received concurrent chemotherapy. However, because dis-
tant metastasis or pleural dissemination was the initial site 
of the disease progression in 18 patients (36%), the use of 
chemotherapy may thus have additional effects on control-
ling the subclinical systemic disease.
The strength of this study is that as a single-institutional 
study it provided complete information on the clinical course 
after surgery including recurrence, failure after radiother-
apy, final outcomes, well-controlled planning, and quality of 
radiotherapy.
There are limitations that need to be acknowledged. 
This study may include the patients whose involved lymph 
nodes were relatively limited in terms of their number and 
their location. Because this retrospective analysis was inher-
ently affected by a selection bias associated with the use 
of radiotherapy, a straightforward comparison between the 
patients who received radiotherapy and the patients who 
did not receive radiotherapy was not allowed. Therefore, 
the real possible benefits of radiotherapy for thoracic lymph 
node recurrence over chemotherapy alone remain uncertain. 
Another limitation, as in other studies of nonsurgical ther-
apies, is the lack of a pathological diagnosis. Lymph node 
sampling under mediastinoscopy or thoracotomy is usually 
impossible or is a high-risk procedure because systematic 
mediastinal lymph node dissection is generally performed 
during the initial surgery. Accurate targeting of an involved 
lymph node by endobronchial ultrasound-guided transbron-
chial needle aspiration requires technical skills and experi-
ence because the anatomy in the mediastinum was affected 
by surgery. FDG-PET was used to make a diagnosis in 31 of 
40 patients without pathological evidence; however, it was 
not available in the remaining nine patients. Even though 
FDG-PET shows good diagnostic performance in detecting 
recurrence in postoperative NSCLC patients with a fairly 
high sensitivity (97%) and specificity (96%) as seen in our 
previous report,16 we could not eliminate the possibility of 
false-positive diagnoses in our study. In addition, the sample 
size of this study was relatively small because this type of 
recurrence is uncommon. Despite these essential shortcom-
ings, the data demonstrated the favorable results of radio-
therapy for patients whose characteristics were described in 
this study.
In conclusion, radiation therapy for thoracic lymph 
node recurrence after complete resection is safe and provides 
acceptable disease control. This treatment provides better out-
comes if the disease is asymptomatic and has a single-station 
involvement. Early detection of thoracic lymph node recur-
rence may therefore improve the effectiveness of this treat-
ment strategy.
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